RT  - European Journal of Gynaecological Oncology
ID  - 10.12892/ejgo3957.2018
T1  - HIPEC treatment in advanced and recurrent ovarian cancer: a meta-analysis of observational studies
A1  - T.H. Dellinger
A1  - D.D. Smith
A1  - E. Ballard
A1  - E. Mikhael
A1  - R.J. Morgan
A1  - B. Lee
A1  - M.T. Wakabayashi
A1  - E.S. Han
K1  - Hyperthermic intraperitoneal chemotherapy; Ovarian cancer; Meta-analysis.
YR  - 2018
SP  - 353
AB  - <p>This meta analysis summarizes survival outcomes of advanced and recurrent ovarian cancer patients undergoing hyperthermic intraperitoneal chemotherapy (HIPEC), from published studies between 1990 and 2015. Objective: The authors performed a meta-analysis on outcomes of patients with advanced (primary) and recurrent epithelial ovarian cancer (EOC) treated with cytoreductive surgery and HIPEC. Materials and Methods: Studies evaluating HIPEC in EOC patients published between January 1, 1990 and January 1, 2015 were identified using PubMed. Eligible studies had ≥ 10 patients and reported overall survival (OS). The authors performed multivariate analysis of OS and progression-free survival (PFS) based on modeling the point estimates with weighted fixed effects models. Results: Twenty-six studies met criteria with extractable statistics (n=1608): 13 advanced (n=534) and 14 recurrent EOC (n=1074). For primary advanced EOC, five-year OS was 39.7% (95% CI: 37.8-41.7%), with a 63-month median OS. For recurrent EOC, five-year OS was 32.0% (95% CI: 30.3-33.7%), with a 39-month median OS. Optimal cytoreduction was achieved in 79% of advanced and 77% of recurrent EOC patients. Mortality was 1.4% (advanced) and 3.9% (recurrent). Conclusions: HIPEC treatment in ovarian cancer in the primary or recurrent setting has favorable survival outcomes as compared to surgical cytoreduction alone, with comparable mortality rates.</p>